A meta-analysis of 346 phase I clinical trials, involving more than 13,000 patients, found that selecting treatment based on a tumor’s molecular characteristics led to significantly better outcomes.
A mutli-center observational study demonstrated the clinical validity and utility of the PROphet non-small cell lung cancer test, a plasma proteome machine learning-based decision-support tool designed to identify patient subsets benefiting from PD-1/PD-L1 inhibitor-based therapies.
